Trial Profile
A Single-centre, Randomised, Double-blind, Two-way Cross-over Trial Investigating the Bio-equivalence in Healthy Male Subjects of NovoSeven (CP-rFVIIa) and a Formulation of NovoSeven Stable at 25°C (VII25)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemophilia
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 05 Jun 2015 New trial record